ClinicalTrials.gg
CompletedNCT06568458Updated Mar 14, 2025

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

A Phase 1 interventional study of Nintedanib and BMS 986278 in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The Purpose of the Study is to Assess the Drug Interaction and Bioavailability of BMS-986278 in Tablet Formulations and the Effect that Food has on BMS-986278 in Tablet Formulation in Healthy Participants

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy males and females (INOCBP)
  • Participant must have (BMI) of 18.0 kg/m2 through 32.0 kg/m2, inclusive.
  • Participant must have Body weight ≥ 50 kg

Exclusion criteria

Exclusion Criteria:

  • Participant must not have current or recent GI disease
  • Participant with evidence of organ dysfunction or any deviation, as determined by investigator, from normal in physical examination, vital signs, 12-lead , or clinical laboratory determinations beyond what is consistent with the target population.
  • Participant with prior exposure to BMS-986278 and exposure of any drug or placebo within 4 weeks of study intervention administration.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Part I: Period A

    Drug: Nintedanib

  • Experimental
    Part I: Period B

    Drug: BMS 986278

  • Experimental
    Part I: Period C

    Drug: Nintedanib · Drug: BMS 986278

  • Experimental
    Part II: Period 1

    Drug: BMS 986278

  • Experimental
    Part II: Period 2

    Drug: BMS 986278

  • Experimental
    Part II: Period 3

    Drug: BMS 986278

  • Experimental
    Part III: Period 1

    Drug: BMS 986278

  • Experimental
    Part III: Period 2

    Drug: BMS 986278

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax)

    Time frame: Days 4, 17, 21 (Part-1); Days 1, 7, 13 (Part-2); Days 1, 7 (Part-3)

  2. Area under the plasma concentration-time curve within a dosing interval AUC(TAU)

    Time frame: Day 4, 17 and 21 of Part 1

  3. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration AUC(0-T)

    Time frame: Day 1-6 (part-2 and Part-3), Day 7-12 (Part2 and 3), Day 13-18) (Part-2)

  4. Area under the plasma concentration-time curve from time zero extrapolated to infinite time AUC(INF)

    Time frame: Day 1-6 (part-2 and Part-3), Day 7-12 (Part2 and 3), Day 13-18) (Part-2)

Secondary outcomes

  1. Number of participants with non-serious AEs (Adverse events)

    Time frame: Up to 28 Days post discontinuation of dosing

  2. Number of participants with Serious AEs

    Time frame: Up to 28 Days post discontinuation of dosing

  3. Number of participants with AEs leading to discontinuation

    Time frame: Up to 28 Days post discontinuation of dosing

  4. Number of participants with Physical examination abnormalities

    Time frame: Up to 28 Days post discontinuation of dosing

  5. Number of participants with vital sign abnormalities

    Time frame: Up to 28 Days post discontinuation of dosing

  6. Number of participants with 12-lead electrocardiogram (ECG) abnormalities

    Time frame: Up to 28 Days post discontinuation of dosing

  7. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 28 Days post discontinuation of dosing

  8. Time of maximum observed plasma concentration (Tmax)

    Time frame: Day 4, 17, 21 (Part-1), Day 1 (part-2 and Part-3), Day 7 (Part2 and 3), Day 13) (Part-2)

  9. Apparent terminal phase half-life (T-HALF)

    Time frame: Day 1-6 (part-2 and Part-3), Day 7-12 (Part2 and 3), Day 13-18) (Part-2)

  10. Apparent total body clearance (CLT/F)

    Time frame: Day 1-6 (part-2 and Part-3), Day 7-12 (Part2 and 3), Day 13-18) (Part-2)

  11. Apparent volume of distribution of terminal phase (Vz/F)

    Time frame: Day 1-6 (part-2 and Part-3), Day 7-12 (Part2 and 3), Day 13-18) (Part-2)

07

Study locations

1 site
  • Local Institution - 0001
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Feb 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 23, 2024
StartActual
Sep 19, 2024
Primary completionActual
Feb 27, 2025
CompletionActual
Feb 27, 2025
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06568458
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Sep 19, 2024
Primary completion
Feb 27, 2025
Completion
Feb 27, 2025
Last update
Mar 14, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · Admilparant

Start the discussion